YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale

PURPOSE: Faricimab is a novel anti–angiopoietin-2 and anti–vascular endothelial growth factor (VEGF) bispecific antibody with high affinities and specificities for both VEGF and angiopoietin-2. It is postulated that targeting angiogenic factors and inflammatory pathways in addition to the VEGF pathw...

Descripción completa

Detalles Bibliográficos
Autores principales: Eter, Nicole, Singh, Rishi P., Abreu, Francis, Asik, Kemal, Basu, Karen, Baumal, Caroline, Chang, Andrew, Csaky, Karl G., Haskova, Zdenka, Lin, Hugh, Ruiz, Carlos Quezada, Ruamviboonsuk, Paisan, Silverman, David, Wykoff, Charles C., Willis, Jeffrey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559760/
https://www.ncbi.nlm.nih.gov/pubmed/36246184
http://dx.doi.org/10.1016/j.xops.2021.100111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559760/
https://www.ncbi.nlm.nih.gov/pubmed/36246184
http://dx.doi.org/10.1016/j.xops.2021.100111

Ejemplares similares